AAF

The 340B Drug Pricing Program: Challenges and Solutions - AAF

New Podcast Episode: A Sobering Inflation Report and Congress’ September To-Do List – AAF

It’s The AAF Exchange – your source for clear, data-driven information on today’s economic and domestic political issues. In this episode of the AAF Exchange, AAF President Douglas Holtz-Eakin joins us to discuss sober thoughts on a sobering inflation report and what to watch for when of Congress’ brief pre-election return to Washington. AAF products …

New Podcast Episode: A Sobering Inflation Report and Congress’ September To-Do List – AAF Read More »

The 340B Drug Pricing Program: Challenges and Solutions - AAF

FTC action on vertical merger could stifle game-changing cancer tech – AAF

The Federal Trade Commission (FTC) recently filed a lawsuit to block an $8 billion vertical merger between medical technology companies Illumina and Grail; For regulatory watchers, this action provides a window into the FTC’s intentions for future oversight of vertical mergers and how the agency views competition in this market. In a new insight, competition …

FTC action on vertical merger could stifle game-changing cancer tech – AAF Read More »

The 340B Drug Pricing Program: Challenges and Solutions - AAF

The 340B Drug Pricing Program: Challenges and Solutions – AAF

Congress established the 340B Drug Pricing Program in 1992 to increase access to lower-cost care for patients. In new research, health care policy analyst Jackson Hammond explores the problems with the 340B program, considers the consequences of the program’s pitfalls, and offers potential solutions. Key points: The 340B drug pricing program has grown dramatically since …

The 340B Drug Pricing Program: Challenges and Solutions – AAF Read More »